Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

(2021) Tara L. Lin et al.   Blood Advances

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

(2021) Jeffrey E Lancet et al.   Lancet Haematology

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)

(2020) Jorge E. Cortes et al.   BLOOD

Introducing patient‐reported outcome in the acute leukemia quality registries in Sweden

(2020) Emma Bergfelt Lennmyr et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective

(2020) Chetasi Talati et al.   Future Oncology

Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial

(2020) Bastien Cabarrou et al.   INVESTIGATIONAL NEW DRUGS

Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia

(2020) Kathleen F. Villa et al.   JOURNAL OF MEDICAL ECONOMICS

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

(2020) Caitlyn T. Solem et al.   CANCER

Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals

(2020) Qi Wang et al.   Nanomedicine-Nanotechnology Biology and Medicine

Health state utilities associated with treatment options for acute myeloid leukemia (AML)

(2019) Louis S. Matza et al.   JOURNAL OF MEDICAL ECONOMICS

A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia

(2019) Carla M Mamolo et al.   Future Oncology

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

(2019) Sarah Bertoli et al.   Cancer Medicine

CPX-351 As First Intensive Therapy for Elderly Patients with AML

(2019) Ellen K. Ritchie et al.   BLOOD

Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia

(2019) Jonathan E. Kolitz et al.   LEUKEMIA & LYMPHOMA

Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper

(2019) Kah Poh Loh et al.   Current Hematologic Malignancy Reports

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

(2018) Jeffrey E. Lancet et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology

(2018) Caitlyn T. Solem et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Measuring quality of life in acute myeloid leukemia: limitations and future directions

(2016) Sarah A. Buckley et al.   Expert Review of Hematology

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

(2015) Lene Sofie Granfeldt Østgård et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia

(2012) E.J. Feldman et al.   LEUKEMIA RESEARCH

Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells

(2011) Hyun Pyo Kim et al.   EXPERIMENTAL HEMATOLOGY

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

(2010) Wah-Seng Lim et al.   LEUKEMIA RESEARCH

Secondary acute myeloid leukemia – a single center experience

(2010) T. Szotkowski et al.   NEOPLASMA